Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Anhui Province Key Laboratory of Cognition and Neuropsychiatric Disorders, Hefei, China.
J Clin Exp Neuropsychol. 2021 Mar;43(2):156-162. doi: 10.1080/13803395.2021.1891207. Epub 2021 Mar 4.
: The Chinese Smell Identification Test (CSIT) was developed specifically for Chinese populations. This work investigated the utility of this test in detecting Parkinson's disease (PD). Olfactory dysfunction is a common non-motor symptom of PD. There are different opinions on the efficacy of drugs for anosmia in PD.: To investigate the olfactory function of Chinese PD patients, verify the effectiveness of the CSIT, and further detect the effects of dopaminergic drugs on anosmia.: In total, 149 PD patients were recruited from the First Affiliated Hospital of Anhui Medical University and 149 healthy comparison participants (HCP) were recruited from the Institute of Psychology of the Chinese Academy of Sciences. The CSIT was used for olfactory function testing in all participants.: CSIT scores were significantly lower in the PD group than in the HCP group (t(296) = -12.797, < 0.001, d = 1.48). Receiver operating characteristic curve analysis showed that the optimal threshold value for the olfactory recognition test was 22.5, which had a sensitivity and specificity of 71.1% and 89.3%, respectively, for the detection of Parkinson's disease. Sex showed a significant influence on CSIT score (t = -3.552, = 0.001), with males being more likely to develop olfactory dysfunction. We found CSIT scores of the non-medication group and the group with medication were lower than those of the HCP group, and the difference was statistically significant (t(82) = -7.116, < 0.0167, d = 1.59; t(82) = -4.907, < 0.0167, d = 1.10). CSIT scores of the group with medication were significantly higher than those of the non-medication group (t(41) = -3.067, < 0.0167, d = 0.41).: In China, the CSIT is recommended to improve the sensitivity of PD detection. The olfactory function of PD patients was improved after treatment with dopaminergic drugs.
: 中国气味识别测试（CSIT）是专为中国人设计的。本研究旨在探讨该测试在中国人群中用于诊断帕金森病（PD）的有效性。嗅觉障碍是 PD 的常见非运动症状。对于 PD 患者嗅觉障碍的药物治疗效果，目前存在不同的观点。
: 本研究旨在调查中国 PD 患者的嗅觉功能，验证 CSIT 的有效性，并进一步检测多巴胺能药物对嗅觉障碍的影响。
: 共招募了 149 名来自安徽医科大学第一附属医院的 PD 患者和 149 名来自中国科学院心理研究所的健康对照组（HCP）。所有参与者均接受 CSIT 嗅觉功能测试。
: PD 组的 CSIT 评分明显低于 HCP 组（t(296) = -12.797, < 0.001, d = 1.48）。受试者工作特征曲线分析显示，嗅觉识别测试的最佳阈值为 22.5，对 PD 的检出率分别为 71.1%和 89.3%。性别对 CSIT 评分有显著影响（t = -3.552, = 0.001），男性更易发生嗅觉功能障碍。我们发现未用药组和用药组的 CSIT 评分均低于 HCP 组，且差异有统计学意义（t(82) = -7.116, < 0.0167, d = 1.59；t(82) = -4.907, < 0.0167, d = 1.10）。用药组的 CSIT 评分明显高于未用药组（t(41) = -3.067, < 0.0167, d = 0.41）。
: 在我国，CSIT 可提高 PD 的检出敏感性。PD 患者经多巴胺能药物治疗后嗅觉功能得到改善。
